natgillin/translations-raw huggingface dataset:
A method of determining the presence of a CD79b protein in a sample suspected of containing said protein, said method comprising exposing said sample to an antibody according to any one of claims 1 to 7 or the immunoconjugate of any one of claims 9 to 11 and determining binding of said antibody or immunoconjugate to said CD79b protein in said sample, wherein binding of the antibody to said protein is indicative of the presence of said protein in said sample; wherein the sample is optionally from a patient suspected of having a B cell proliferative disorder, optionally lymphoma, non-Hodgkins lymphoma (NHL), aggressive NHL, relapsed aggressive NHL, relapsed indolent NHL, refractory NHL, refractory indolent NHL, chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma, leukemia, hairy cell leukemia (HCL), acute lymphocytic leukemia (ALL), and mantle cell lymphoma. 
Postupak za određivanje prisutnosti CD79b proteina u uzorku za koji se pretpostavlja da sadrži spomenuti protein, naznačen time, da postupak obuhvaća izlaganje spomenutog uzorka protutijelu prema bilo kojem zahtjevu od 1 do 7 ili imunokonjugatu prema bilo kojem zahtjevu od 10 do 12, te određivanje vezanja spomenutog protutijela ili imunokonjugata za spomenuti CD79b protein u spomenutom uzorku, gdje vezanje protutijela na spomenuti protein pokazuje prisutnost spomenutog proteina u spomenutom uzorku; pri čemu je uzorak opcijski od pacijenta za kojega se pretpostavlja da ima proliferativni poremećaj B stanice, opcijski limfom, non-Hodgkins limfom (NHL), agresivni NHL, povratni agresivni NHL, povratni indolentni NHL, refraktorni NHL, refraktorni indolentni NHL, kronična limfocitna leukemija (CLL), limfom malih limfocita, leukemija, leukemija stanica dlaka (HCL), akutna limfocitna leukemija (ALL), i limfom pokrivenih krvnih stanica.
A pharmaceutical composition comprising a therapeutically effective amount of a compound as defined in claim 1 or 2 along with one or more of pharmaceutically acceptable carriers, excipients or diluents. 
Farmaceutski pripravak, naznačen time, da sadrži terapijsku učinkovitu količinu spoja koji je definiran u patentnom zahtjevu 1 ili 2 u kombinaciji s jednim ili više farmaceutski prihvatljivih nosača, ekscipijensa ili razrjeđivača.
A pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 1 or 2, along with one or more of pharmaceutically acceptable carriers, excipients or diluents and at least one other compound selected from ß2- agonists, corticosteroids, leukotriene antagonists, 5-lipoxygenase inhibitors, chemokine inhibitors, p38 kinase inhibitors, anticholinergics, antiallergics, PAF (platelet activating factor) antagonists, EGFR (epidermal growth factor receptor) kinase inhibitors, muscarinic receptor antagonists or combination(s) thereof. 
Farmaceutski pripravak, naznačen time, da sadrži terapijsku učinkovitu količinu spoja iz patentnog zahtjeva 1 ili 2, u kombinaciji s jednim ili više farmaceutski prihvatljivih nosača, ekscipijensa ili razrjeđivača i najmanje jednim dodatnim spojem odabranim između: 62-agonista, kortikosteroida, antagonista leukotriena, inhibitora 5-lipoksigenaze, inhibitora kemokina, inhibitora p38 kinaze, antikolinergika, antialergika, antagonista PAF (faktor aktiviranja trombocita), inhibitora kinaze EGFR-a (receptora epidermalnog faktora rasta), antagonista muskarinskih receptora ili njihovih kombinacija.
A compound of claim 1 or 2 or a pharmaceutical composition of claim 3 or 4 for use in the treatment, prevention, inhibition or suppression of multiple sclerosis, AIDS, rejection of transplant, rheumatoid arthritis, bronchitis, chronic obstructive pulmonary disease (COPD), asthma, psoriasis, allergic rhinitis, shock, atopic dermatitis, Crohn's disease, adult respiratory distress syndrome (ARDS), eosinophilic granuloma, allergic conjunctivitis, osteoarthritis, colitis, pancreatitis, and cancer in a mammal. 
Spoj iz patentnog zahtjeva 1 ili 2 ili farmaceutski pripravak iz patentnog zahtjeva 3 ili 4, naznačen time, da se koristi za liječenje, prevenciju, inhibiranje ili supresiju multipla skleroze, AIDS-a, odbacivanja presadka, reumatoidnog artritisa, bronhitisa, kronične opstruktivne plućne bolesti (COPD), astme, psorijaze, alergijskog rinitisa, šoka, atopijskog dermatitisa, Crohnove bolesti, sindroma respiratornog distresa odraslih osoba (ARDS), eozinofilnog granuloma, alergijskog konjunktivitisa, osteoartritisa, kolitisa, pankreatitisa i karcinoma u sisavca.
reacting a compound of Formula II with a compound of Formula III to give a compound of Formula IV, 
reakciju spoja Formule II sa spojem Formule III, čime se dobiva spoj Formule IV, [image]
reacting the compound of Formula VIII with a compound of Formula IX to give a compound of Formula X, 
reakciju spoja Formule VIII sa spojem Formule IX, čime se dobiva spoj Formule X, [image]
reducing the compound of Formula X to give a compound of Formula XI, 
redukcija spoja Formule X, čime se dobiva spoj Formule XI, [image]
reacting the compound of Formula XI with hydroxylamine hydrochloride to give a compound of Formula XII, 
reakciju spoja Formule XI s hidroksilamin hidrokloridom, čime se dobiva spoj Formule XII, [image]
(c) cyclizing the compound of Formula XVI to give a compound of Formula XVI (a), 
cikliranje spoja Formule XVI, čime se dobiva spoj Formule XVI (a),
reducing the compound of Formula XXV to give a compound of Formula XXVI, 
redukciju spoja Formule XXV, čime se dobiva spoj Formule XXVI, [image]
cyclizing the compound of Formula XXVI to give a compound of Formula XXVII, wherein R1a is alkyl, X is halogen, R1, R2 and R3 are the same as defined in claim 1. 
cikliranje spoja Formule XXVI, čime se dobiva spoj Formule XXVII, u kojem R1a je alkil, X je halogen, R1, R2 i R3 definirani su jednako kao u patentnom zahtjevu 1.
deprotecting a compound of Formula XXVIII to give a compound of Formula XXIX, 
skidanje zaštite sa spoja Formule XXVIII, čime se dobiva spoj Formule XXIX, [image]
reducing the compound of Formula XXXIII to give a compound of Formula XXXIII (a), 
redukciju spoja Formule XXXIII, čime se dobiva spoj Formule XXXIII (a),
deprotecting a compound of Formula XXXIV (a) to give a compound of Formula XXXIV, 
skidanje zaštite sa spoja Formule XXXIV (a) [image] čime se dobiva spoj Formule XXXIV,
reacting the compound of Formula XXXIV with a compound of Formula XXXV R'-X Formula XXXV to give a compound of Formula XXXVI, wherein Pr is a protecting group, X is halogen, R' is alkyl, cycloalkyl or cycloalkylalkyl, and R1, R2, R3 and M are the same as defined in claim 1. 
reakciju spoja Formule XXXIV sa spojem Formule XXXV R'-X Formula XXXV čime se dobiva spoj Formule XXXVI, u kojem Pr je zaštitna skupina, X je halogen, R' je alkil, cikloalkil ili cikloalkilalkil, a R1, R2, R3 i M definirani su jednako kao u patentnom zahtjevu 1.
deprotecting a compound of Formula XXXVII to give a compound of Formula XXXVIII, 
skidanje zaštite sa spoja Formule XXXVII [image] čime se dobiva spoj Formule XXXVIII,
reacting the compound of Formula XLI with a compound of Formula XXXV R'—X Formula XXXV to give a compound of Formula XLII, 
reakciju spoja Formule XLI sa spojem Formule XXXV R'—X Formula XXXV čime se dobiva spoj Formule XLII,
debenzylating the compound of Formula XLII to give a compound of Formula XLIII, wherein Pr is a protecting group, X is a halogen, R' is alkyl, cycloalkyl or cycloalkylalkyl and R1, R2, R3, M and m are the same as defined in claim 1. 
uklanjanje skupine benzil iz spoja Formule XLII, čime se dobiva spoj Formule XLIII, u kojem Pr je zaštitna skupina, X je halogen, R' je alkil, cikloalkil ili cikloalkilalkil, a R1, R2, R3, M i m definirani su jednako kao u patentnom zahtjevu 1.
reacting a compound of Formula V with a compound of Formula VI (a) to give a compound of Formula XLIV, 
reakciju spoja Formule V sa spojem Formule VI (a), čime se dobiva spoj Formule XLIV, [image]
oxidising the compound of Formula XLIV to give a compound of Formula XLV, 
oksidiranje spoja Formule XLIV, čime se dobiva spoj Formule XLV, [image]
hydrolysing the compound of Formula XLV to give a compound of Formula XLVI, 
hidroliziranje spoja Formule XLV, čime se dobiva spoj Formule XLVI, [image]
reacting the compound of Formula XLVIII with hydroxylamine hydrochloride to give a compound of Formula XLIX, 
reakciju spoja Formule XLVIII s hidroksilamin hidrokloridom, čime se dobiva spoj Formule XLIX, [image]
heating a compound of Formula LI to give a compound of Formula LII, 
zagrijavanje spoja Formule LI, čime se dobiva spoj Formule LII, [image]
reacting the compound of Formula LII with phosphorous oxy halide to give a compound of Formula LIII, 
reakciju spoja Formule LII s fosfornim oksihalidom, čime se dobiva spoj Formule LIII, [image]
hydrolysing the compound of Formula LV to give a compound of Formula LVI, 
hidroliziranje spoja Formule LV, čime se dobiva spoj Formule LVI, [image]
reacting the compound of Formula LVI with a compound of Formula IX to give a compound of Formula LVII, 
reakciju spoja Formule LVI sa spojem Formule IX, čime se dobiva spoj Formule LVII, [image]
deprotecting the compound of Formula LVII to give a compound of Formula LVIII, 
skidanje zaštite sa spoja Formule LVII, čime se dobiva spoj Formule LVIII, [image]
reacting the compound of Formula LVIII with a compound of Formula LIX to give a compound of Formula LX, 
reakciju spoja Formule LVIII sa spojem Formule LIX, čime se dobiva spoj Formule LX, [image]
reducing the compound of Formula LX to give a compound of Formula LXI, 
redukciju spoja Formule LX, čime se dobiva spoj Formule LXI, [image]
reacting the compound of Formula LXI with hydroxylamine hydrochloride to give a compound of Formula LXII, 
reakciju spoja Formule LXI s hidroksilamin hidrokloridom, čime se dobiva spoj Formule LXII, [image]
reacting the compound of Formula LXII with a compound of Formula XIII to give a compound of Formula LXIII, 
reakciju spoja Formule LXII sa spojem Formule XIII, čime se dobiva spoj Formule LXIII, [image]
deprotecting the compound of Formula LXIII to give a compound of Formula LXIV, 
skidanje zaštite sa spoja Formule LXIII, čime se dobiva spoj Formule LXIV, [image]
reacting a compound of Formula LIII with a compounds of Formula VI to give a compound of Formula LV (a), 
reakciju spoja Formule LIII sa spojevima Formule VI, čime se dobiva spoj Formule LV (a), [image]
hydrolysing the compound of Formula LV(a) to give a compound of Formula LVI (a), 
hidroliziranje spoja Formule LV (a), čime se dobiva spoj Formule LVI (a), [image]
reacting the compound of Formula LVI (a) with a compound of Formula IX to give a compound of Formula LVII (a), 
reakciju spoja Formule LVI (a) sa spojem Formule IX, čime se dobiva spoj Formule LVII (a), [image]
deprotecting the compound of Formula LVII (a) to give a compound of Formula LVIII (a), 
skidanje zaštite sa spoja Formule LVII (a), čime se dobiva spoj Formule LVIII (a), [image]
reacting the compound of Formula LVIII (a) with a compound of Formula LIX to give a compound of Formula LX (a), 
reakciju spoja Formule LVIII (a) sa spojem Formule LIX, čime se dobiva spoj Formule LX (a), [image]
reducing the compound of Formula LX (a) to give a compound of Formula LXI (a), 
redukcija spoja Formule LX (a), čime se dobiva spoj Formule LXI (a), [image]
reacting the compound of Formula LXI (a) with hydroxylamine hydrochloride to give a compound of Formula LXII (a), 
reakciju spoja Formule LXI (a) s hidroksilamin hidrokloridom, čime se dobiva spoj Formule LXII (a), [image]
reacting the compound of Formula LVII (a) with a compound of Formula XIII to give a compound of Formula LXIII (a), wherein X is halogen, R1a is alkyl, Pr is a protecting group, R3b is alkyl or cycloalkyl and R1, R2, R3 and M are the same as defined in claim 1. 
reakciju spoja Formule LVII (a) sa spojem Formule XIII [image] čime se dobiva spoj Formule LXIII (a), u kojem X je halogen, R1a je alkil, Pr je zaštitna skupina, R3b je alkil ili cikloalkil, a R1, R2, R3 i M definirani su jednako kao u patentnom zahtjevu 1.
protecting a compound of Formula LXVIII to give a compound of Formula LXIX, 
skidanje zaštite sa spoja Formule LXVIII, čime se dobiva spoj Formule LXIX, [image]
reacting the compound of Formula LXIX with sodium cyanide to give a compound of Formula LXX, 
reakciju spoja Formule LXIX s natrijevim cijanidom, čime se dobiva spoj Formule LXX,
hydrolysing the compound of Formula LXX to give a compound of Formula LXXI, 
hidroliziranje spoja Formule LXX, čime se dobiva spoj Formule LXXI,
cyclizing the compound of Formula LXX to give a compound of Formula LXXII, 
cikliranje spoja Formule LXX, čime se dobiva spoj Formule LXXII,
reacting the compound of Formula LXVIII with a compound of Formula LXXIII R4X Formula LXXIII to give a compound of Formula LXXIV, wherein X is halogen, Pr1 is a protecting group and R1, R2, R3, R4, m and M are the same as defined in claim 1. 
reakciju spoja Formule LXVIII sa spojem Formule LXXIII X Formula LXXIII čime se dobiva spoj Formule LXXIV, u kojem X je halogen, Pr1 je zaštitna skupina, a R1, R2, R3, R4, m i M definirani su jednako kao u patentnom zahtjevu 1.
hydrolysing a compound of Formula LXXVI to give a compound of Formula LXXI, 
hidroliziranje spoja Formule LXXVI [image] čime se dobiva spoj Formule LXXI,
reacting the compound of Formula LXXI with ammonium carbonate or a compound of Formula LXXV R4NHR'4 Formula LXXV to give a compound of Formula LXXV (a) or a compound of LXXV (b) repectively, wherein R1a is alkyl, and R1, R2, R3, R4, R'4, m and M are the same as defined in claim 1. 
reakciju spoja Formule LXXI s amonijevim karbonatom ili spojem Formule LXXV NHR4 Formula LXXV čime se dobiva spoj Formule LXXV (a), odnosno spoj LXXV (b), u kojem R1a je alkil, a R1, R2, R3, R4, R'4, m i M definirani su jednako kao u patentnom zahtjevu 1.
reacting a compound of Formula LXIX with sodium azide to give a compound of Formula LXXVII, 
reakciju spoja Formule LXIX s natrijevim azidom, čime se dobiva spoj Formule LXXVII, [image]
reducing the compound of Formula LXXVII to give a compound of Formula LXXVIII, 
redukciju spoja Formule LXXVII, čime se dobiva spoj Formule LXXVIII,
A PDE type 7A inhibitor or dual PDE type 4B /PDE type 7A inhibitor for use in treating, preventing, inhibiting or suppressing inflammatory diseases, CNS diseases or autoimmune diseases, in a mammal, having the structure of Formula Ia, or its pharmaceutically acceptable salts, wherein R'1a is hydrogen, alkyl, alkenyl, alkynyl, acyl, aryl, aralkenyl, aralkyl, cycloalkyl alkyl, heteroaryl, heterocyclylalkyl, heteroarylalkyl, cycloalkyl or heterocyclyl; 
Inhibitor PDE 7A ili dvostruki inhibitor PDE 4B/PDE 7A, naznačen time, da se koristi za liječenje, prevenciju, inhibiranje ili supresiju upalnih bolesti, bolesti CNS-a ili autoimunosne bolesti u sisavca, kojemu je građa sukladna Formuli Ia, [image] ili njegove farmaceutski prihvatljive soli, u kojoj R'1a je vodik, alkil, alkenil, alkinil, acil, aril, aralkenil, aralkil, cikloalkil alkil, heteroaril, heterociklilalkil, heteroarilalkil, cikloalkil ili heterociklil;
A PDE type 7A inhibitor or dual PDE type 4B /PDE type 7A inhibitor for use in the treatment, prevention, inhibition or suppression of multiple sclerosis, AIDS, rejection of transplant, rheumatoid arthritis, bronchitis, chronic obstructive pulmonary disease (COPD), asthma, psoriasis, allergic rhinitis, shock, atopic dermatitis, Crohn's disease, adult respiratory distress syndrome (ARDS), eosinophilic granuloma, allergic conjunctivitis, osteoarthritis, colitis, pancreatitis, and cancer in a mammal. having the structure of Formula Ia, or its pharmaceutically acceptable salts, wherein R'1a is hydrogen, alkyl, alkenyl, alkynyl, acyl, aryl, aralkenyl, aralkyl, cycloalkyl alkyl, heteroaryl, heterocyclylalkyl, heteroarylalkyl, cycloalkyl or heterocyclyl; 
Inhibitor PDE 7A ili dvostruki inhibitor PDE 4B/PDE 7A, naznačen time, da se koristi za liječenje, prevenciju, inhibiranje ili supresiju multipla skleroze, AIDS-a, odbacivanja presadka, reumatoidnog artritisa, bronhitisa, kronične opstruktivne plućne bolesti (COPD), astme, psorijaze, alergijskog rinitisa, šoka, atopijskog dermatitisa, Crohnove bolesti, sindroma respiratornog distresa odraslih osoba (ARDS), eozinofilnog granuloma, alergijskog konjunktivitisa, osteoartritisa, kolitisa, pankreatitisa i karcinoma u sisavca, kojemu je građa sukladna Formuli Ia, [image] ili njegove farmaceutski prihvatljive soli, u kojoj R'1a je vodik, alkil, alkenil, alkinil, acil, aril, aralkenil, aralkil, cikloalkil alkil, heteroaril, heterociklilalkil, heteroarilalkil, cikloalkil ili heterociklil;
Use of vegetable fat, protein and carbohydrate, for the preparation of a liquid infant milk formula wherein at least 15 wt.% of fat droplets have a diameter of 5-25 micrometer based on total weight of fat for feeding an infant. 
Upotreba biljne masti, proteina i ugljikohidrata, u pripravi tekuće mliječne formule za dojenčad, naznačena time što najmanje 15%, težinski, masnih kapi ima promjer od 5-25 mikrometara, na osnovu ukupne težine masti za ishranu dojenčeta.
The use according to claim 1, wherein the concentration of fat in the upper 10 volume% of the liquid infant milk formula is 3 to 8 g/100 ml and wherein the concentration of fat in the lower 10 volume% of the liquid infant milk formula is 1 to 3 g/100 ml. 
Upotreba u skladu s patentnim zahtjevom 1, naznačena time što koncentracija masti u gornjih 10% volumena tekuće mliječne formule za dojenčad je 3 do 8 g/100 ml, a koncentracija masti u donjih 10% volumena tekuće mliječne formule za dojenčad je 1 do 3 g/100 ml.
The use according to claim 4, wherein said concentration ratio of fat is established at the start of a feeding event in a total volume of at least 30 ml. 
Upotreba u skladu s patentnim zahtjevom 4, naznačena time što je navedeni koncentracijski omjer masti uspostavljen na početku hranjenja u ukupnom volumenu od najmanje 30 ml.
A container containing a single liquid infant milk formula according to any of the preceding claims wherein said liquid infant milk formula has a volume of 20 to 300 ml. 
Spremnik koji sadrži jednu tekuću mliječnu formulu za dojenčad u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što navedena tekuća mliječna formula za dojenčad ima volumen od 20 do 300 ml.
preparing a liquid nutritional composition comprising vegetable fat, carbohydrate and protein, comprising at least 15 wt.% fat droplets with a diameter of 5-25 micrometer based on total weight of fat; 
priprave tekućeg prehrambenog pripravka koji sadrži biljnu mast, ugljikohidrat i protein i ima najmanje 15%, težinski, masnih kapi s promjerom od 5-25 mikrometara, na osnovu ukupne težine masti;
leaving liquid nutritional composition obtained in step b undisturbed for at least 5 minutes, preferably at least 10 minutes. 
ostavljanja tekućeg prehrambenog pripravka pripravljenog u koraku b) na miru najmanje 5 minuta, po mogućnosti najmanje 10 minuta.
Use of the liquid infant milk formula obtained by the process according to claim 7 for the preparation for a composition for feeding an infant. 
Upotreba tekuće mliječne formule za dojenčad pripravljene postupkom u skladu s patentnim zahtjevom 7, naznačena time što je mliječna formula namijenjena pripravi pripravka za ishranu dojenčeta.
Powder comprising vegetable fat, protein and carbohydrate, suitable for making a liquid infant milk formula, wherein at least 15 wt.% of the total amount of fat droplets have a diameter of 5-25 micrometer. 
Prašak koji sadrži biljnu mast, protein i ugljikohidrat, naznačen time što je pogodan za pripravu tekuće mliječne formule za dojenčad, gdje najmanje 15%, težinski, ukupne količine masnih kapi ima promjer od 5-25 mikrometara.
a phenyl group, a naphthyl group or an isoquinolinyl group, each of which may be substituted with 1 to 3 substituents selected from the group B [wherein the group B consists of a halogen atom, a C1-C6 alkyl group, a C1-C6 alkoxy group, an amino group which may be substituted with one or two C1-C6 alkyl groups, a morpholino group, a piperazino group which may be substituted with a C1-C6 alkyl group(s), a C1-C6 alkanoylamino group, and a C1-C6 alkylsulfonylamino group], 
fenilnu skupinu, naftil skupinu ili izokinolinil skupinu, od kojih svaka može biti supstituirana sa 1 do 3 supstituenta odabrana iz skupine B [pri čemu skupina B sadrži atom halogena, C1-C6 alkilnu skupinu, C1-C6 alkoksi skupinu, amino skupinu koja može biti supstituirana sa jednom ili dvije C1-C6 alkilne skupine, morfolino skupinu, piperazino skupinu koja može biti supstituirana sa C1-C6 alkil skupinom(ama), C1-C6 alkanoilamino skupinu, te C1-C6 alkilsulfonilamino skupinu], predstavlja atom vodika ili C1-C6 alkilnu skupinu, i
represents a hydrogen atom or a C1-C6 alkyl group, and R5 represents a phenyl group, a thienyl group, a thiazolyl group, a pyridyl group, a naphthyl group, an indanyl group, a dihydrobenzofuranyl group, a benzodioxolyl group, a benzothiadiazolyl group, a benzothienyl group or a quinolinyl group, each of which may be substituted with I to 5 substituents selected from the group C [wherein the group C consists of a C1-C6 alkyl group, a halogen atom, a trifluoromethyl group, a C1-C6 alkoxy group, a trifluoromethoxy group, a nitro group, a cyano group, and a C2-C7 alkanoyl group], or a C2-C8 alkenyl group which may be substituted with a phenyl group(s)}, wherein the following compound is excluded: 
predstavlja fenilnu skupinu, tienil skupinu, tiazolil skupinu, piridil skupinu, naftil skupinu, indanil skupinu, dihidrobenzofuranil skupinu, benzodioksolil skupinu, benzotiadiazolil skupinu, benzotienil skupinu ili kinolinil skupinu, od kojih svaka može biti supstituirana sa 1 do 5 supstituenta odabranih iz skupine C [pri čemu skupina C sadrži C1-C6 alkilnu skupinu, atom halogena, trifluorometilnu skupinu, C1-C6 alkoksi skupinu, trifluorometoksi skupinu, nitro skupinu, cijano skupinu, te C2-C7 alkanoil skupinu], ili C2-C8 alkenil skupinu koja može biti supstituirana sa fenilnom skupinom(ama)}, pri čemu je isključen slijedeći spoj: -lodo-N-(2-metoksipiridin-4-ilmetil)benzensulfonamid [image] .
A compound represented by formula (I) or a pharmaceutically acceptable salt thereof; for use in a medical treatment method: {wherein Y1 represents a nitrogen atom or a group represented by CRA, Y2 represents a nitrogen atom or a group represented by CRB, Y3 represents a nitrogen atom or a group represented by CRC, RA, RB and RC, which may be the same or different, each represent a hydrogen atom or a C1-C6 alkyl group (excluding the case where Y1 is CRA, Y2 is CRB and Y3 is CRC), X represents an oxygen atom, a sulfur atom, a group represented by the formula -SO-, a group represented by the formula -SO2-, or a group represented by the formula -NR6- (wherein R6 represents a hydrogen atom or a C1-C6 alkyl group), R1 represents a hydrogen atom, a C1-C6 alkyl group, or a benzyl group, R2 represents a hydrogen atom, a C1-C6 alkyl group, or a C3-C8 cycloalkyl group, R3 represents 
predstavlja atom dušika ili skupinu predstavljenu sa CRA, predstavlja atom dušika ili skupinu predstavljenu sa CRB, predstavlja atom dušika ili skupinu predstavljenu sa CRC, RA, RB i RC, koji mogu biti isti ili različiti, svaki predstavlja atom vodika ili C1-C6 alkilnu skupinu (isključujući slučaj gdje Y1 je CRA, Y2 je CRB i Y3 je CRC), X predstavlja atom kisika, atom sumpora, skupinu prikazanu sa formulom -SO-, skupinu prikazanu sa formulom -SO2-, ili skupinu prikazanu sa formulom -NR6- (pri čemu R6 predstavlja atom vodika ili C1-C6 alkilnu skupinu),
The antibody of any preceding claim, which binds to an epitope within a region of CD79b from amino acid 29-39 of SEQ ID NO: 2 or amino acid 1-11 of SEQ ID NO: 16. 
Protutijelo prema zahtjevu 1, naznačeno time, da se protutijelo veže na epitop unutar područja od CD79b amino kiseline 29-39 od SEQ ID NO: 2 ili amino kiseline 1-11 od SEQ ID NO: 16.